Granulocyte-Macrophage Colony-Stimulating Factor Market Size was valued at USD 0.23 Billion in 2023. The Global Granulocyte-Macrophage Colony-Stimulating Factor industry is projected to grow from USD 0.47 Billion in 2024 to USD 1.66 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.43% during the forecast period (2024 - 2032).
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor and immune modulator, which is also known as colony stimulating factor 2. GM-CSF is produced by macrophages, T cells, endothelial cells, and fibroblasts. It promotes neutrophil maturation and proliferation. Neutrophils are the type of white blood cells important part of the innate immune system. It is used as a supporting agent in cancer treatment increases the immunity in a cancer patient, use after bone marrow transplantation to stimulate white blood cell proliferation, also use in dendritic cell vaccines. The key factor responsible for influencing this market is the increasing prevalence of cancer, fungal infection, unsuccessful skin grafting resolution. According to the World Health Organization (WHO), in 2015, cancer was the second leading cause of death which can support the GM-CSF market growth. However, factors such as the high cost of chemotherapy treatments, and side effects associated with the drug are expected to restrict the granulocyte-macrophage-colony-stimulating factor market growth during the forecast period.
The granulocyte-macrophage-colony-stimulating factor market is segmented on the basis of route of administration, application, and end-user. The granulocyte-macrophage-colony-stimulating factor market, by route of administration, is sub-segmented into subcutaneous bolus and intravenous infusion. The granulocyte-macrophage-colony-stimulating factor market on the bases of application it is segmented into fungal infections, skin-graft, cut-burn wounds, acute myelogenous leukemia and other. On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, research centers, and others. On the basis of region, the granulocyte-macrophage-colony-stimulating factor market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Some of the key players in the granulocyte-macrophage-colony-stimulating factor market are Xconomy, Inc., Partner Therapeutics (PTx), Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA and others.
Granulocyte-Macrophage Colony-Stimulating Factor Market Share (%), by Region, 2017
Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health
It is estimated that North America dominated the granulocyte-macrophage-colony-stimulating factor market owing to the increasing innovations in cancer research, clinical practice and access to cancer treatment in this region. National Cancer Institute (NCI) April 2018, article states that 1,735,350 new cases of cancer will be diagnosed in the United States in 2018. This influences the market growth in this region.
Europe stood second largest in the granulocyte-macrophage-colony-stimulating factor market owing to the increasing use of blood and bone marrow transplantation to treat blood diseases, cancer treatment, and immune disorders. According to the National Center for Biotechnology Information (NCBI) article 2016, that there were more than 40,000 hematopoietic stem cell transplantation in Europe in 2014. It also included Eastern European countries has shown growth in transplant activities. Such growth and a high number of transplantations in this region facilitate the market growth.
Asia-Pacific was projected to be the fastest growing region for the granulocyte-macrophage-colony-stimulating factor market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of pharynx cancer and oral cavity in 2017 in Japan. Such a high incidence of cancer favors the market growth in this region.
The Middle East and Africa holds the least share of the granulocyte-macrophage-colony-stimulating factor market due to the presence of poor health expenditure, low income, and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.
Xconomy, Inc., Partner Therapeutics (PTx), Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA, and others.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 1.66 Billion |
| CAGR | 10.43 % (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Route of Administration, By Application, By End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Xconomy, Inc., Partner Therapeutics (PTx), Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA and others. |
| Key Market Opportunities | Increasing cancer rates drive demand for GM-CSF therapies to boost white blood cell counts during treatment. |
| Key Market Drivers | Growing cancer incidence boosts demand for GM-CSF in chemotherapy and immunotherapy. |
Frequently Asked Questions (FAQ) :
The high cost of chemotherapy and side-effects can hold back Granulocyte-Macrophage Colony-Stimulating Factor Market growth.
The segments are subcutaneous bolus and intravenous infusion that have been discussed in the Granulocyte-Macrophage Colony-Stimulating Factor Market.
The segments of Granulocyte-Macrophage Colony-Stimulating Factor Market are acute myelogenous leukemia, fungal infections, skin-graft, cut-burn wounds, and others.
The end users of Granulocyte-Macrophage Colony-Stimulating Factor Market report are surgical centers, diagnostic centers, research centers, hospitals and clinics, and others.
North America would be the dominating force of Granulocyte-Macrophage Colony-Stimulating Factor Market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
